Impact of frailty on the management of patients with gynecological cancer aged 80 years and older.

Elisabeth ReiserNina PötschVeronika SeebacherAlexander ReinthallerFriedrich WimazalEdith FleischmannMichael KrainerReinhart HorvatStephan PolterauerChristoph Grimm

Published in: Archives of gynecology and obstetrics (2020)

Majority of patients was able to receive standard therapy, as suggested by the tumor board, irrespective of age and frailty. Nonetheless, frailty is a common finding in patients with gynecological malignancy aged 80 years and older. Frail patients show shorter progression-free, and overall survival within this cohort.

Keyphrases

community dwelling
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
squamous cell carcinoma
middle aged
patient reported outcomes
mesenchymal stem cells
papillary thyroid
bone marrow